Article

Frater, J, Ewer, KJ, Ogbe, A, Pace, M, Adele, S, Adland, E, Alagaratnam, J, Aley, PK, Ali, M, Ansari, MA, Bara, A, Bittaye, M, Broadhead, S, Brown, A, Brown, H, Cappuccini, F, Cooney, E, Dejnirattisai, W, Dold, C, Fairhead, C et al, Fok, H, Folegatti, PM, Fowler, J, Gibbs, C, Goodman, AL, Jenkin, D, Jones, M, Makinson, R, Marchevsky, NG, Mujadidi, YF, Nguyen, H, Parolini, L, Petersen, C, Plested, E, Pollock, KM, Ramasamy, MN, Rhead, S, Robinson, H, Robinson, N, Rongkard, P, Ryan, F, Serrano, S, Tipoe, T, Voysey, M, Waters, A, Zacharopoulou, P, Barnes, E, Dunachie, S, Goulder, P, Klenerman, P, Screaton, GR, Winston, A, Hill, AVS, Gilbert, SC, Pollard, AJ, Fidler, S, Fox, J, Lambe, T, Oxford COVID Vaccine Trial Group, and Tahmasebi, F (2021) Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. The lancet. HIV, 8 (8). e474-e485. ISSN 2405-4704